- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07659795
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer (TARGET-D 203)
14. september 2026 oppdatert av: Verastem, Inc.
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203)
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer
Studieoversikt
Status
Rekruttering
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Antatt)
150
Fase
- Fase 2
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Verastem Call Center
- Telefonnummer: 7812924204
- E-post: VS-7375-203TrialSupport@verastem.com
Studer Kontakt Backup
- Navn: Luke Chung, MD
- E-post: VS-7375-203Medical@verastem.com
Studiesteder
-
-
New South Wales
-
Macquarie Park, New South Wales, Australia, 2109
- Rekruttering
- Macquarie University Hospital
-
Ta kontakt med:
- Sam Ly
- Telefonnummer: +612 9812 3538
- E-post: sam.ly@mq.edu.au
-
Ta kontakt med:
- Jignasa Mahida
- Telefonnummer: +61 466 476 498
- E-post: Jignasa.mahida@mq.edu.au
-
Hovedetterforsker:
- Andrew Parsonson, MBBS MMed (Clin Epi) FRACP
-
-
Queensland
-
South Brisbane, Queensland, Australia, 4101
- Rekruttering
- ICON Cancer Centre South Brisbane
-
Ta kontakt med:
- Icon Cancer Centre South Brisbane
- Telefonnummer: 07 3737 4700
- E-post: admin.southbrisbane@icon.team
-
Hovedetterforsker:
- Jermaine Coward, MBBS, MRCP (UK), FRACP, PhD
-
-
South Australia
-
Kurralta Park, South Australia, Australia, 5037
- Rekruttering
- Icon Cancer Centre Adelaide
-
Ta kontakt med:
- Icon Cancer Centre Adelaide/Kurralta Park
- Telefonnummer: 08 8474 0220
- E-post: admin.adelaide@icon.team
-
Hovedetterforsker:
- Carolyn Bampton, MBBS, FRACP
-
-
-
-
California
-
Los Angeles, California, Forente stater, 90025
- Rekruttering
- START Los Angeles
-
Ta kontakt med:
- START Hope Team
- Telefonnummer: 424-465-1820
- E-post: hopeteam@startresearch.com
-
Hovedetterforsker:
- Navid Hafez, M.D., MPH
-
Los Angeles, California, Forente stater, 90067
- Rekruttering
- Valkyrie Clinical Trials (contact for more locations)
-
Hovedetterforsker:
- David Berz, MD, PhD, MPH
-
Ta kontakt med:
- Trenis Palmer, PhD
- Telefonnummer: 912-398-3205
- E-post: trenis.palmer@vctcare.com
-
-
Florida
-
Tampa, Florida, Forente stater, 33612
- Rekruttering
- Moffitt Cancer Center
-
Hovedetterforsker:
- Tiago Biachi de Castria, MD, PhD
-
Ta kontakt med:
- Cheyenne Schneider
- Telefonnummer: 813-745-3691
- E-post: Cheyenne.Schneider@moffitt.org
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46202
- Rekruttering
- Indiana University, Simon Comprehensive Cancer Center
-
Ta kontakt med:
- Yvonne LaFary
- Telefonnummer: 317-278-5613
- E-post: ylafary@iu.edu
-
Hovedetterforsker:
- Anita Turk, M.D.
-
-
Michigan
-
Grand Rapids, Michigan, Forente stater, 49546
- Rekruttering
- START MidWest
-
Ta kontakt med:
- START Hope Team
- Telefonnummer: 616-954-5554
- E-post: hopeteam@startresearch.com
-
Hovedetterforsker:
- Sreenivasa R Chandana, M.D., Ph.D.
-
-
Missouri
-
St Louis, Missouri, Forente stater, 63110
- Rekruttering
- Washington University
-
Hovedetterforsker:
- Kian-Huat Lim, M.D., Ph.D.
-
Ta kontakt med:
- Caroline Bumb
- Telefonnummer: 314-747-4000
- E-post: cbumb@wustl.edu
-
-
New Jersey
-
East Brunswick, New Jersey, Forente stater, 08816
- Rekruttering
- START New Jersey
-
Ta kontakt med:
- START Hope Team
- Telefonnummer: 732-426-4750
- E-post: hopeteam@startresearch.com
-
Hovedetterforsker:
- Bruno S Fang, M.D.
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37203
- Rekruttering
- Sarah Cannon Research Institute Oncology Partners
-
Hovedetterforsker:
- Meredith Pelster, MD
-
Ta kontakt med:
- ASK SARAH
- Telefonnummer: 877-691-7274
- E-post: askSARAH@scresearch.net
-
-
Texas
-
Fort Worth, Texas, Forente stater, 76104
- Rekruttering
- START Dallas Fort Worth
-
Ta kontakt med:
- START Hope Team
- Telefonnummer: 682-350-3010
- E-post: hopeteam@startresearch.com
-
Hovedetterforsker:
- Salwan Al Mutar, M.D., M.Sc.
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- The University of Texas MD Anderson Cancer Center
-
Hovedetterforsker:
- Christine Parseghian, MD
-
Ta kontakt med:
- MD Anderson Cancer Center, GI Medical Oncology Dept
- Telefonnummer: 855-982-0789
- E-post: GIClinicalTrials@mdanderson.org
-
-
Utah
-
West Valley City, Utah, Forente stater, 84119
- Rekruttering
- START Mountain Region
-
Ta kontakt med:
- START Hope Team
- Telefonnummer: 801-907-4750
- E-post: hopeteam@startresearch.com
-
Hovedetterforsker:
- José M Pacheco, M.D.
-
-
Virginia
-
Charlottesville, Virginia, Forente stater, 22908
- Rekruttering
- UVA Comprehensive Cancer Center
-
Hovedetterforsker:
- Matthew Reilley, MD
-
Ta kontakt med:
- Clinical Trials Navigator
- Telefonnummer: 434-982-0539
- E-post: UVACANCERTRIALS@uvahealth.org
-
-
Washington
-
Seattle, Washington, Forente stater, 98101
- Rekruttering
- Virginia Mason Medical Center
-
Ta kontakt med:
- Cancer Research Team
- Telefonnummer: 206-287-6270
- E-post: crp@benaroyaresearch.org
-
Hovedetterforsker:
- Jessica Lee, DO
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Beskrivelse
Inclusion Criteria:
- Histopathology confirmed metastatic CRC
- Measurable disease per RECIST 1.1
- Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)
ECOG PS=0 or 1
2L+ patients:
- Must have received at least 1 standard chemotherapy for metastatic colorectal adenocarcinoma
- Have documented disease progression during or following their most recent prior line of therapy
Have either stable disease, partial response (PR), or complete response (CR) by RECIST v1.1 as the best overall response (BOR) during at least 1 prior systemic therapy.
1L patients:
- Treatment-naïve or received no more than 1 cycle of standard systemic therapy for metastatic disease.
Exclusion Criteria:
- Have any other documented co-existing common RAS mutation(s)
- Prior anti-cancer Tx within 4 weeks or drug-specific timeline within first treatment dose, whichever shorter
- Major surgery within 4 weeks of first treatment dose
- Radiation therapy (RT) within 1 week of first treatment dose
- Receipt of prior direct RAS inhibitor
- Receipt of more than 1 investigational therapy
- Untreated or symptomatic CNS metastasis
- Receipt of strong CYP3A4 inhibitor/inducer or CYP3A4 sensitive substrates with narrow therapeutic index within 14 days or drug-specific timeline within first treatment dose, whichever is shorter
- Receipt of PPI or H2 blocker within 5 days
- Inability to swallow oral medication
- Other protocol-defined inclusion/exclusion criteria may apply
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: VS-7375 Monotherapy or Preferred Combination in 2L+ CRC
Participants randomized to a treatment in 2:1 ratio
|
Intravenøs infusjon
Taken by mouth
Intravenous infusion
|
|
Eksperimentell: VS-7375 with chosen regimen in 2L+ CRC
|
Intravenøs infusjon
Taken by mouth
Intravenous infusion
|
|
Eksperimentell: VS-7375 + cetuximab and mFOLFOX in 1L CRC
|
Intravenous infusion
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1 - 2L CRC only
Tidsramme: 6 months
|
Overall Response Rate per RECIST version 1.1, per blinded independent central review (BICR)
|
6 months
|
|
To characterize the safety and tolerability of VS-7375 monotherapy or in combination with cetuximab or panitumumab, administered on a daily oral schedule in participants with KRAS G12D-mutated 2L+ CRC
Tidsramme: 6 months
|
Proportion/number of participants with AEs, TEAEs, TRAEs, SAEs, and dose interruptions/reductions and discontinuations
|
6 months
|
|
To characterize the safety and tolerability of VS-7375 in combination with cetuximab + mFOLFOX, administered on a daily oral schedule in participants with KRAS G12D-mutated 1L CRC
Tidsramme: 6 months
|
Proportion/number of participants with AEs, TEAEs, TRAEs, SAEs, and dose interruptions/reductions and discontinuations
|
6 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Plasma Pharmacokinetics (PK) of VS-7375 and relevant metabolites, Cmax
Tidsramme: 20 weeks
|
Maximum concentration (Cmax)
|
20 weeks
|
|
Plasma Pharmacokinetics (PK) of VS-7375 and relevant metabolites, AUC
Tidsramme: 20 weeks
|
Area under plasma Concentration (AUC) 0 to t
|
20 weeks
|
|
To evaluate Pharmacodynamics (PD) and other relevant blood tumor markers specific to tumor type
Tidsramme: Up to 2.5 years
|
CA19-9, CEA, CA-125
|
Up to 2.5 years
|
|
Confirmed ORR per RECIST v1.1 assessed by BICR (primary) and Investigator (secondary) assessments
Tidsramme: 24 months
|
To evaluate additional efficacy parameters of VS-7375 monotherapy and VS-7375 in combination with cetuximab or panitumumab or cetuximab + mFOLFOX, administered on a daily oral schedule in participants with KRAS G12D-mutated CRC
|
24 months
|
|
To assess the health-related quality of life and disease based on European Organization for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire Core module C30 (QLQ-C30)
Tidsramme: 24 months
|
The EORTC QLQ-C30 is a validated questionnaire to assess the quality of life of colorectal cancer patients
|
24 months
|
|
Time to next therapy
Tidsramme: 24 months
|
To assess the interval between initiation of study treatment and initiation of subsequent treatment
|
24 months
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Imaging of tumor metabolism changes in 2L monotherapy patients
Tidsramme: 24 months
|
To assess tumor metabolism dynamics on FDG-PET/CT
|
24 months
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
28. juli 2026
Primær fullføring (Antatt)
1. juni 2027
Studiet fullført (Antatt)
1. desember 2028
Datoer for studieregistrering
Først innsendt
15. juni 2026
Først innsendt som oppfylte QC-kriteriene
15. juni 2026
Først lagt ut (Faktiske)
22. juni 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
16. september 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
14. september 2026
Sist bekreftet
1. juli 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter nettsted
- Neoplasmer
- Tarmsykdommer
- Gastrointestinale neoplasmer
- Neoplasmer i fordøyelsessystemet
- Sykdommer i fordøyelsessystemet
- Gastrointestinale sykdommer
- Intestinale neoplasmer
- Rektale sykdommer
- Kolonsykdommer
- Kolorektale neoplasmer
- Aminosyrer, peptider og proteiner
- Proteiner
- Antistoffer, monoklonalt, humanisert
- Antistoffer, monoklonalt
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Panitumumab
- Cetuximab
Andre studie-ID-numre
- VS-7375-203
- 2026-526473-42-00 (Ctis)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
JA
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Ja
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .